Investment Rating - The report assigns a rating of "Buy" for PICC Group with a target price of HK$7.5, implying a 0.72x 2026E P/EV [11] - For PICC Group A-shares, the target price is set at Rmb8.1, implying a 2026E Price/EV multiple of 0.86x [13] - PICC P&C is rated "Buy" with a target price of HK$21.2, based on a three-stage model [15] Core Insights - The consensus from the Citi China Conference 2025 indicates that commercial health insurance in China is transitioning from a supplementary role to an essential component of the healthcare system, potentially creating a market size of Rmb2-3 trillion [2][3] - The implementation of Diagnosis-Related Groups (DRG) reforms is identified as a primary catalyst for the demand for commercial insurance, leading to a dual-track system where commercial insurance covers innovative medical services not accommodated by the public system [3][4] - The new commercial insurance innovative drug catalog is expected to facilitate market access for pharmaceutical companies, allowing for reimbursement and sales of innovative drugs without the constraints of DRG payment limits [4] Market Dynamics - The healthcare market is projected to shift from individual-focused policies to group insurance, indicating the emergence of a more sophisticated corporate payer class [5] - The non-critical illness health segment is expected to grow at a double-digit CAGR, providing a significant funding source for high-cost innovative therapies and premium medical services [8] - The demand for integrated health management services is anticipated to create new B2B opportunities for service providers [7]